scientific reports

OPEN



Exploration of IncRNA/ circRNA-miRNA-mRNA network in patients with chronic atrophic gastritis in Tibetan plateau areas based on DNBSEQ-G99 RNA sequencing

Wen Pan^{1,2}, Chao Liu³, Tao Ren³, Xiaohong Chen³, Cuiting Liang³, Jin Wang¹ & Jinlin Yang¹

A higher incidence of chronic atrophic gastritis (CAG) is generally considered as a precancerous lesion in gastric cancer (GC). The aim of this study was to identify potential molecules involved in the pathogenesis of CAG in the Tibetan plateau, hoping to help the diagnosis and management of the disease. Atrophic and non-atrophic gastric mucosal tissue samples were collected from seven patients with chronic gastritis (CG). Differentially expressed IncRNAs, circRNAs, miRNAs, and mRNAs between CAG and chronic non-atrophic gastritis (CNAG) groups were identified based on DNBSEQ-G99 RNA sequencing. Subsequently, competitive endogenous RNA (ceRNA) regulatory networks (IncRNA/ circRNA-miRNA-mRNA networks) were constructed. Two datasets (GSE153224 and GSE163416), involving data from non-Tibetan plateau areas, were used to further screen out Tibetan plateau key mRNAs, followed by the common genes of Tibetan plateau key and ferroptosis-related mRNAs were also identified. Functional enrichment analyses were performed to investigate the biological functions of Tibetan plateau mRNAs in the CAG. A total of seven IncRNA-miRNA-mRNA relationship pairs and 424 circRNA-miRNA-mRNA relationship pairs were identified in this study. The relationship pairs of hsa_circ_0082984-hsa-miR-204-5p-CACNG8, IncRNA DRAIC/has_circ_0008561-hsa-miR-34a-5p-AR/ GXYLT2, IncRNA GAS1RR/RGMB-AS1/hsa_circ_0008561-hsa-miR-3614-5p-TMEM216/SUSD5, and LINC00941/hsa_circ_0082984-hsa-miR-873-3p-TMC5 can be involved in the pathogenesis of CAG. Additionally, eight common genes of Tibetan plateau key and ferroptosis-related differentially expressed mRNAs (DEmRNAs) (CBS, SLC2A4, STAT3, ALOX15B, ATF3, IDO1, NOX4, and SOCS1) were identified in CAG. The common genes of Tibetan plateau key and ferroptosis-related DEmRNAs can play a role in the JAK-STAT signaling pathway. This study identified important molecular biomarkers that may be involved in regulating the pathological mechanisms of CAG in the Tibetan plateau, which provides potential research directions for future research.

Keywords Chronic atrophic gastritis, Tibetan plateau areas, RNA sequencing, circRNA-miRNA-mRNA, lncRNA-miRNA-mRNA

Chronic gastritis (CG) manifests as chronic atrophic gastritis (CAG) and chronic non-atrophic gastritis (CNAG)¹. CNAG may progress to CAG, which is characterized by gastric mucosal atrophy, degeneration intrinsic glands, intestinal metaplasia, and eventually gastric cancer (GC)². As a precancerous lesion of intestinal-type GC, CAG is a digestive system disease characterized by atrophy of the gastric mucosal glands, caused by various pathogenic

¹Department of Gastroenterology and Hepatology, West China Hospital of Sichuan University, 37 Guoxue Lane, Wuhou District, Chengdu 610054, Sichuan, China. ²Department of Health Management Center, The Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region, Chengdu, Sichuan, China. ³Department of Gastroenterology and Hepatology, The Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region, Chengdu, Sichuan, China. ^{Sie}email: yangjinlin@wchscu.cn factors^{3,4}. The most common symptoms of CAG include epigastric pain, bloating, abdominal discomfort, and anorexia⁵. Owing to the important role of early diagnosis and treatment in preventing the occurrence of GC, CAG has received more attention in recent years. However, timely diagnosis of CAG remains difficult in clinical practice due to the lack of specificity of clinical symptoms. Currently, CAG is usually diagnosed using endoscopy and pathological examination⁶. However, endoscopic and histological assessments of mucosal atrophy have some limitations, as well as inaccurate localization and misdiagnosis due to inappropriate histopathological examination of section⁷. Therefore, there is an urgent need to identify new diagnostic biomarkers with high sensitivity and specificity for early diagnosis of CAG, with real-time clinical applications.

Tibet is located in the southwestern part of the Qinghai-Tibet Plateau, with an average altitude of over 4000 m, and is known as the third pole in the world⁸. Due to its important geographical and strategic location, medical research in plateau areas has gradually emerged and attracted considerable attention in recent years. In contrast to other areas, most areas in Tibet are high-altitude areas with perennial low oxygen, low pressure, severe cold, relatively poor sanitary conditions, high Helicobacter pylori (mainly east asian type) infection rate⁹, common bile reflux, high salt, fat, and high purine food intake, leading to a high incidence of CAG. However, few studies have been conducted on patients in plateau areas, hindering specific studies on the pathogenesis, early diagnosis, and treatment of CAG in Tibetan plateau areas. Therefore, it is necessary to further explore the molecular development mechanism of CAG in Tibetan plateau areas to provide a theoretical basis for the diagnosis, treatment, and pathogenesis of the disease.

Noncoding RNAs (ncRNAs) are functional RNA molecules that are not translated into proteins, including long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs)¹⁰, which can act as microRNA (miRNA) sponges, compete with the same corresponding miRNA response element (MRE), and effectively control the subsequent post-transcriptional regulation of miRNA¹¹. LncRNAs can act as cis-acting factors to regulate the expression of neighboring genes in the genome, and can also act as trans-acting elements to regulate gene transcription¹². In addition, lncRNAs may affect the post-transcriptional modification of mRNA. Therefore, lncRNAs are attractive candidates as new diagnostic biomarkers for CAG. Studies have shown that circRNAs have miRNA complementary binding sites and interact with miRNAs to play a regulatory role in diseases¹³, showing great potential to be used as biomarkers and therapeutic targets¹⁴⁻¹⁶. However, there are few reports on the RNAmediated regulatory network in CAG, and there are still some deficiencies in the general understanding of this network. Therefore, a systematic understanding of CAG-associated RNA molecular mechanisms is crucial for developing new strategies for early diagnosis and therapeutic intervention of CAG.

To explore the molecular development mechanism of CAG in the Tibetan plateau, we collected atrophic and non-atrophic gastric mucosal tissue samples from seven Tibetan patients with CG. Differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs between CAG and CNAG groups were identified based on DNBSEQ-G99 RNA sequencing. Based on this information, competitive endogenous RNA (ceRNA) regulatory networks (lncRNA/circRNA-miRNA-mRNA network) were developed and GO and KEGG enrichment analyses were performed to detect the biological functions of Tibetan plateau mRNAs. The flowchart of this study is shown in Fig. 1. This study contributes to the identification of potential biomarkers for CAG.

Materials and methods

Participants from the Tibetan plateau region

Seven CAG patients from the Tibetan plateau were included in this study. The inclusion criteria to be a participant were as follows: (1) patients belonged to the Tibetan plateau region; (2) patients ranged between 18 and 70 years of age; (3) CAG patients who met the endoscopic diagnosis and pathological diagnosis criteria (the diagnostic criteria are based on the Chinese Consensus on chronic gastritis proposed in 2012); (4) CAG patients who met the determination indicators of pepsinogen, serum gastrin, and immunological examination; and (5) routine endoscopic evaluation of patients with CNAG with lymphocyte infiltration in the gastric mucosa of the gastric antrum. Exclusion criteria for the above individuals were as follows: (1) patients under the age of 18 or over 70 years; (2) patients with gastric ulcer, duodenal ulcer, special type of gastritis, or gastrointestinal bleeding; (3) histopathological examination showing gastric mucosal atrophic changes, dysplasia, or suspicious malignant transformation; (4) patients with a history of gastric surgery; (5) patients with severe heart, lung, liver, kidney, or blood system complications or suffering from life-threatening diseases; (6) patients with a history of mental disorders, or alcohol/drug abuse; (7) female patients who were going to give birth, pregnancy, or breastfeeding. Detailed clinical information of these individuals is showed in Table 1. Atrophic mucosal tissue samples (CAG group) and non-atrophic mucosal tissue samples (CNAG group) from seven CAG patients were collected for further analysis. The atrophic mucosal tissue samples and non-atrophic mucosal tissue samples were obtained from the greater and lesser curvature of the stomach of the same patient, respectively. All participants provided written informed consent. The study was approved by the Ethics Committee of Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region (Ethics Approval Number: 202137).

LncRNA library construction, sequencing, and raw data processing

Ribosomal RNA was removed from total RNA using the RNase H method. The purified RNA was fragmented, and one-strand cDNA and two-strand cDNA with DUTP were synthesized in a PCR apparatus. Subsequently, terminal repair and connection of the sequencing connector were performed. The two-stranded cDNA containing the U strand was digested with UDG enzymes and simultaneously subjected to PCR amplification to complete the library preparation. Qualified libraries were sequenced for lncRNA, mRNA and circRNA using PE100 strategy on DNBSEQ-G99 platform. The raw data were quality-controlled using fastp software to obtain high-quality clean data. Specifically, adapter sequence, 5' segment, 3' segment, bases with quality < 20 and reads with N > 10% were trimmed. The high-quality clean data of lncRNA and mRNA were aligned to the human



Figure 1. The flowchart of this study.

reference genome (GRCh38) using the HISAT2 program. In addition, high-quality clean data of circRNA was compared and analyzed using the CIRIquant tool.

MiRNA library construction, sequencing, and raw data processing

The length of 18–30 nt RNA was recovered from the total RNA. Reverse transcription PCR amplification was performed after addition of adapters at the 3' and 5' ends. Subsequently, the cDNA was amplified using highly sensitive polymerase. Library inspection and pooling looping were performed to obtain qualified libraries. Qualified libraries were sequenced for miRNA using SE50 strategy on DNBSEQ-G99 platform. The raw data were quality-controlled using fastp software to obtain high-quality clean data. Specifically, joint sequence, bases with quality <20 and reads with N > 10% were trimmed. Subsequently, the high-quality clean data after quality control were aligned and annotated using QuickMIRSeq.

Differential expression analysis and functional annotation

EdgeR package was used to identify differentially expressed lncRNAs (DElncRNAs), differentially expressed miRNAs (DEmiRNAs), and differentially expressed mRNAs (DEmRNAs) between the CAG and CNAG groups. CIRIquant was used to identify differentially expressed circRNAs (DEcircRNAs). DElncRNAs, DEmiRNAs, DEmRNAs, and DEcircRNAs were screened out under the screening criteria of | log fold change (FC) |>1 and P<0.05. The "pheatmap" and "ggplot2" packages were used to plot the heat maps and volcano maps, respectively. In addition, the clusterProfiler package was used for Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analyses of DEmRNAs. KEGG contains numerous signaling pathways^{17–19}. Significantly enriched GO and KEGG terms were identified under the screening conditions of P<0.05.

Identification of target cis/trans-acting DEmRNAs of DEIncRNAs

Based on the different modes of action of lncRNAs and target mRNAs, target mRNA prediction was divided into Cis and Trans groups. The mode of action of Cis is to use genome annotation and genome browser to identify possible target mRNAs of lncRNA, which generally refers to mRNA within 100 kb upstream and downstream of lncRNA. Target mRNAs transcribed in the same direction in the promoter region generally promote expression, whereas those transcribed in the opposite direction inhibit expression. $|\mathbf{r}|$ represents the correlation coefficient between lncRNA and mRNA, which is used to measure the degree of linear correlation between lncRNA and mRNA expression levels in the same sample. A positive value of r indicates a positive correlation, while a negative value of r indicates a negative correlation. The screening criteria for target cis-acting mRNAs of lncRNAs were $|\mathbf{r}| > 0.8$ and P < 0.05. $|\mathbf{r}| > 0.8$ indicates that only lncRNA-mRNA pairs with absolute correlation coefficients

| Number | Sex | Age (years) | BMI | Altitude (m) | WBC (10^9/L) | HGB (g/L) | RBC (10^12/L) | PLT (10^9/L) | ALT (U/L) | AST (U/L) | CRE (umol/L) | UREA (umol/L) |
|---|---|--|--|--|---|--|---|--|---|---|--|---|
| CNAG1 | Male | 62 | 28.2 | 3650 | 6.38 | 182 | 5.92 | 202 | 38 | 21 | 67 | 3.39 |
| CNAG2 | Male | 45 | 23.9 | 3650 | 4.94 | 143 | 4.78 | 216 | 53 | 23 | 77 | 5.75 |
| CNAG3 | Male | 34 | 24.6 | 3600 | 7.04 | 184 | 5.88 | 232 | 35 | 31 | 80 | 4.9 |
| CNAG4 | Male | 59 | 23.2 | 3253 | 5.33 | 141 | 4.46 | 146 | 19 | 15 | 63 | 3.44 |
| CNAG5 | Male | 62 | 26 | 4350 | 6.81 | 160 | 5.11 | 130 | 27 | 17 | 75 | 4.25 |
| CNAG6 | Female | 53 | 30.4 | 4350 | 6.55 | 148 | 5.04 | 264 | 28 | 12 | 52 | 5.66 |
| CNAG7 | Female | 54 | 24.5 | 3670 | 5.75 | 138 | 4.49 | 324 | 20 | 14 | 57 | 4.51 |
| CAG1 | Male | 62 | 28.2 | 3650 | 6.38 | 182 | 5.92 | 202 | 38 | 21 | 67 | 3.39 |
| CAG2 | Male | 45 | 23.9 | 3650 | 4.94 | 143 | 4.78 | 216 | 53 | 23 | 77 | 5.75 |
| CAG3 | Male | 34 | 25.2 | 3600 | 7.04 | 184 | 5.88 | 232 | 35 | 31 | 80 | 4.9 |
| CAG4 | Male | 59 | 23.2 | 3253 | 5.33 | 141 | 4.46 | 146 | 19 | 15 | 63 | 3.44 |
| CAG5 | Male | 62 | 26 | 4350 | 6.81 | 160 | 5.11 | 130 | 27 | 17 | 75 | 4.25 |
| CAG6 | Female | 53 | 30.4 | 4350 | 6.55 | 148 | 5.04 | 264 | 28 | 12 | 52 | 5.66 |
| CAG7 | Female | 54 | 24.5 | 3670 | 5.75 | 138 | 4.49 | 324 | 20 | 14 | 57 | 4.51 |
| | | | | | | | | | | | Samples metaplasia | |
| Number | Sex | blood sugar (mmol/L) | BUA (mmol/L) | Smoking history | Alcohol history | NSAIDS | Hormone | CCVD | MS | ICD | Samples met | aplasia |
| Number CNAG1 | Sex Male | blood sugar (mmol/L) 6.71 | BUA (mmol/L) 290 | Smoking history Yes | Alcohol history Yes | NSAIDS No | Hormone No | CCVD No | MS Yes | ICD No | Samples met Intestinal me | aplasia taplasia |
| Number CNAG1 CNAG2 | Sex Male Male | blood sugar (mmol/L) 6.71 5.14 | BUA (mmol/L) 290 387 | Smoking historyYesNo | Alcohol history Yes No | NSAIDS No No | Hormone No No | CCVD No No | MS Yes No | ICD No No | Samples met Intestinal me Intestinal me | aplasia taplasia taplasia |
| Number CNAG1 CNAG2 CNAG3 | Sex Male Male Male | blood sugar (mmol/L) 6.71 5.14 4.69 | BUA (mmol/L) 290 387 439 | Smoking historyYesNoNo | Alcohol history Yes No No | NSAIDS No No No | Hormone No No No | CCVD No No No | MS Yes No No | ICD No No No | Samples met Intestinal me Intestinal me Intestinal me | a plasia taplasia taplasia taplasia |
| Number CNAG1 CNAG2 CNAG3 CNAG4 | Sex Male Male Male Male | blood sugar (mmol/L) 6.71 5.14 4.69 5.5 | BUA (mmol/L) 290 387 439 376 | Smoking history Yes No No Yes | Alcohol history Yes No No Yes | NSAIDS No No No No | Hormone No No No No | CCVD No No No No | MS Yes No No No | ICD No No No | Samples met Intestinal me Intestinal me Intestinal me | taplasia taplasia taplasia taplasia taplasia |
| Number CNAG1 CNAG2 CNAG3 CNAG4 CNAG5 | Sex Male Male Male Male Male | blood sugar (mmol/L) 6.71 5.14 4.69 5.5 4.63 | BUA (mmol/L) 290 387 439 376 460 | Smoking history Yes No No Yes Yes | Alcohol history Yes No No Yes Yes | NSAIDS No No No No No | Hormone No No No No No | CCVD No No No No No | MS Yes No No Yes | ICD No No No No No | Samples met Intestinal me Intestinal me Intestinal me Intestinal me | aplasia taplasia taplasia taplasia taplasia taplasia |
| Number CNAG1 CNAG2 CNAG3 CNAG4 CNAG5 CNAG6 | Sex Male Male Male Male Male Female | blood sugar (mmol/L) 6.71 5.14 4.69 5.5 4.63 5.03 | BUA (mmol/L) 290 387 439 376 460 236 | Smoking historyYesNoNoYesYesNo | Alcohol history Yes No No Yes Yes No | NSAIDS No No No No No No | Hormone No No No No No No | CCVD No No No No Yes | MS Yes No No Yes No | ICD No No No No No | Samples met Intestinal me Intestinal me Intestinal me Intestinal me No | aplasia taplasia taplasia taplasia taplasia taplasia |
| Number CNAG1 CNAG2 CNAG3 CNAG4 CNAG5 CNAG6 CNAG7 | Sex Male Male Male Male Female Female | blood sugar (mmol/L) 6.71 5.14 4.69 5.5 4.63 5.03 4.54 | BUA (mmol/L) 290 387 439 376 460 236 296 | Smoking historyYesNoNoYesYesNoNoNo | Alcohol history Yes No Yes Yes No No | NSAIDS No No No No No No | Hormone No No No No No No | CCVD No No No No Yes No | MS Yes No No Yes No No | ICD No No No No No No | Samples met Intestinal me Intestinal me Intestinal me Intestinal me No No | aplasia taplasia taplasia taplasia taplasia taplasia |
| Number CNAG1 CNAG2 CNAG3 CNAG4 CNAG5 CNAG6 CNAG6 CNAG7 CAG1 | Sex Male Male Male Male Female Female Male | blood sugar (mmol/L) 6.71 5.14 4.69 5.5 4.63 5.03 4.54 6.71 | BUA (mmol/L) 290 387 439 376 460 236 296 290 | Smoking historyYesNoNoYesYesNoNoYesYes | Alcohol history Yes No Yes Yes No No Yes | NSAIDS No No No No No No No | Hormone No No No No No No No | CCVD No No No No Yes No No | MS Yes No No Yes No No Yes | ICD No No No No No No No | Samples met Intestinal me Intestinal me Intestinal me Intestinal me No No Intestinal me | aplasia taplasia taplasia taplasia taplasia taplasia |
| Number CNAG1 CNAG2 CNAG3 CNAG4 CNAG5 CNAG6 CNAG6 CNAG7 CAG1 CAG2 | Sex Male Male Male Male Female Female Male Male | blood sugar (mmol/L) 6.71 5.14 4.69 5.5 4.63 5.03 4.54 6.71 5.14 | BUA (mmol/L) 290 387 439 376 460 236 296 290 387 | Smoking historyYesNoNoYesYesNoNoYesNoYesNo | Alcohol history Yes No Yes Yes No No Yes No | NSAIDS No No No No No No No No | Hormone No No No No No No No No | CCVD No No No No Yes No No No | MS Yes No No Yes No Yes No | ICD No No No No No No No | Samples met Intestinal me Intestinal me Intestinal me No No Intestinal me Intestinal me | aplasia taplasia taplasia taplasia taplasia taplasia taplasia taplasia |
| Number CNAG1 CNAG2 CNAG3 CNAG4 CNAG5 CNAG5 CNAG6 CNAG7 CAG1 CAG2 CAG3 | Sex Male Male Male Male Female Female Female Male Male Male | blood sugar (mmol/L) 6.71 5.14 4.69 5.5 4.63 5.03 4.54 6.71 5.14 4.69 | BUA (mmol/L) 290 387 439 376 460 236 296 290 387 439 | Smoking historyYesNoNoYesNoNoYesNoYesNoNoNoNoNo | Alcohol history Yes No Yes Yes No Yes No Yes No | NSAIDS No No No No No No No No No | Hormone No No No No No No No No No | CCVD No No No No Yes No No No No | MS Yes No No Yes No Yes No No No | ICD No No No No No No No No | Samples met Intestinal me Intestinal me Intestinal me Intestinal me No No Intestinal me Intestinal me | aplasia taplasia taplasia taplasia taplasia taplasia taplasia taplasia taplasia |
| Number CNAG1 CNAG2 CNAG3 CNAG4 CNAG5 CNAG6 CNAG7 CAG1 CAG1 CAG2 CAG3 CAG4 | Sex Male Male Male Male Female Female Male Male Male Male Male | blood sugar (mmol/L) 6.71 5.14 4.69 5.5 4.63 5.03 4.54 6.71 5.14 4.69 5.5 | BUA (mmol/L) 290 387 439 376 460 236 296 290 387 439 376 | Smoking historyYesNoNoYesYesNoNoYesNoNoYesNoYesYes | Alcohol history Yes No Yes Yes No No Yes No No Yes | NSAIDS No No No No No No No No No No | Hormone No No No No No No No No No No | CCVD No No No No Yes No No No No No | MS Yes No No Yes No Yes No No No No | ICD No No No No No No No No No | Samples met Intestinal me Intestinal me Intestinal me Intestinal me No No Intestinal me Intestinal me Intestinal me | aplasia taplasia taplasia taplasia taplasia taplasia taplasia taplasia taplasia taplasia |
| Number CNAG1 CNAG2 CNAG3 CNAG4 CNAG5 CNAG6 CNAG7 CAG1 CAG2 CAG3 CAG3 CAG4 CAG5 | Sex Male Male Male Male Female Female Female Male Male Male Male Male | blood sugar (mmol/L) 6.71 5.14 4.69 5.5 4.63 5.03 4.54 6.71 5.14 4.69 5.5 4.63 | BUA (mmol/L) 290 387 439 376 460 236 296 290 387 439 387 439 376 460 | Smoking historyYesNoYesYesNoNoYesNoYesNoYesYesYesYesYesYesYesYesYesYesYes | Alcohol history Yes No Yes Yes No No Yes No No Yes Yes Yes | NSAIDS No No No No No No No No No No No | Hormone No No No No No No No No No No No | CCVD No No No No Yes No No No No No No | MS Yes No No Yes No Yes No No No Yes | ICD No No No No No No No No No No | Samples met Intestinal me Intestinal me Intestinal me Intestinal me No No Intestinal me Intestinal me Intestinal me Intestinal me | aplasia taplasia taplasia taplasia taplasia taplasia taplasia taplasia taplasia taplasia taplasia taplasia |
| Number CNAG1 CNAG2 CNAG3 CNAG4 CNAG5 CNAG6 CNAG7 CAG1 CAG2 CAG3 CAG3 CAG4 CAG5 CAG6 | Sex Male Male Male Male Female Female Male Male Male Male Male Female | blood sugar (mmol/L) 6.71 5.14 4.69 5.5 4.63 5.03 4.54 6.71 5.14 4.69 5.5 4.63 5.5 4.63 5.03 | BUA (mmol/L) 290 387 439 376 460 236 296 290 387 439 376 439 376 460 236 | Smoking historyYesNoYesYesNoNoYesNoYesNoYesYesYesYesYesYesYesYoo | Alcohol history Yes No Yes Yes No No Yes Yes Yes Yes No | NSAIDS No No No No No No No No No No No No | Hormone No | CCVD No No No No Yes No No No No No No Yes | MS Yes No No Yes No Yes No No Yes No Yes No | ICD No No No No No No No No No No No | Samples met Intestinal me Intestinal me Intestinal me Intestinal me No No Intestinal me Intestinal me Intestinal me Intestinal me Intestinal me | aplasia taplasia taplasia taplasia taplasia taplasia taplasia taplasia taplasia taplasia taplasia |

Table 1. Clinical information registry. *CNAG* chronic non-atrophic gastritis; *CAG* chronic atrophic gastritis; *BMI* body mass index; *WBC* white blood cell; *HGB* hemoglobin; *RBC* red blood cell; *PLT* platelet; *ALT* alanine transaminase; *AST* aspartate transaminase; *CRE* creatinine; *UREA* urea nitrogen; *BUA* blood uric acid; *NSAIDS* Non-steroidal anti-inflammatory drugs; *CCVD* cardiovascular and cerebrovascular disease; *MS* metabolic syndrome; *ICD* Immune complex disease.

greater than 0.8 are selected as candidate relationship pairs for cis-acting. This standard indicates a strong linear correlation. The trans action mode suggests that the function of lncRNA is not only related to the position of the coding mRNA but is also related to protein-coding genes co-expressed with lncRNA. The screening criteria for target trans-acting mRNAs of lncRNAs were $|\mathbf{r}|>0.95$ and P<0.05. $|\mathbf{r}|>0.95$ indicates that only lncRNA-mRNA pairs with absolute correlation coefficients greater than 0.95 are selected as candidate relationship pairs for trans-acting. This standard indicates a strong linear correlation. The lncRNA-mRNA regulatory network was visualized using Cytoscape.

CeRNA network construction of lncRNA/circRNA-miRNA-mRNA

The miRWalk database was used to identify miRNA-mRNA targeting relationships and screen out experimentally validated targeting relationship pairs. The ENCORI database was used to identify the target pairs of lncRNA-miRNA and circRNA-miRNA. CeRNA network of lncRNA/circRNA-miRNA-mRNA were constructed after the fusion of different relationship pairs.

Further difference analyses of molecules in Tibetan plateau areas based on online dataset (involved non-Tibetan plateau areas)

Two datasets, including data from non-Tibetan plateau areas, were downloaded from the Gene Expression Omnibus (GEO) database: the GSE153224 dataset (Changchun area) and GSE163416 dataset (Wuxi area). In addition, the data were standardized and normalized. The edgeR package was used to analyze the DEmRNAs and DElncRNAs of CAG patients using the screening criteria of |logFC| > 1 and P < 0.05. The intersection of the DEmRNAs and DElncRNAs between the Tibetan and non-Tibetan plateau area was taken to obtain Tibetan plateau key DEmRNAs. The Venn in R package was used to create a Venn diagram. In addition, 283 ferroptosis

driver and suppressor mRNAs were identified in a previous report²⁰. The common genes of Tibetan plateau key and ferroptosis-related DEmRNAs were further identified in patients with CAG.

Results

Screening of DEIncRNAs, DEcircRNAs, DEmiRNAs, and DEmRNAs in Tibetan plateau areas

A total of 750 DEmRNAs, 24 DEmiRNAs, 242 DElncRNAs, and 1353 DEcircRNAs were identified between CAG and CNAG groups. Volcano and heatmaps of these molecules are shown in Fig. 2.

Target mRNAs prediction of IncRNAs in Tibetan plateau areas

According to the screening criteria of $|\mathbf{r}| > 0.8$ and P < 0.05, 15 cis-acting lncRNA-mRNA relationship pairs (including 25 mRNAs) were identified. In addition, according to the screening criteria of $|\mathbf{r}| > 0.95$ and p value < 0.05, 3028 trans-acting lncRNA-mRNA relationship pairs (including 390 mRNAs) were identified. The lncRNA-mRNA regulatory network is shown in Fig. 3, which includes 3049 lncRNA-mRNA relationship pairs and 397 mRNAs. In the lncRNA-mRNA regulatory network, pink, green, circles and rhombuses represent upregulated, down-regulated, mRNAs and lncRNAs, respectively.

CeRNA networks construction of lncRNA/circRNA-miRNA-mRNA in Tibetan plateau areas

The ceRNA (lncRNA/circRNA-miRNA-mRNA) network was developed by integrating lncRNA/circRNA-miRNA and miRNA-mRNA relationship pairs. Seven lncRNA-miRNA-mRNA (involving five mRNAs) relationship pairs (LINC00941-hsa-miR-873-3p-TMC5, GAS1RR-hsa-miR-3614-5p-TMEM216, GAS1RR-hsa-miR-3614-5p-SUSD5, RGMB-AS1-hsa-miR-3614-5p-TMEM216, RGMB-AS1-hsa-miR-3614-5p-SUSD5, DRAIC-hsa-miR-34a-5p-AR and DRAIC-hsa-miR-34a-5p-GXYLT2) were identified in lncRNA-miRNA network (Fig. 4). In the lncRNA-miRNA network, pink, blue, rectangles, triangles and V-shaped represent up-regulated, down-regulated, mRNAs, miRNAs and lncRNAs, respectively. LINC00941-hsa-miR-873-3p-TMC5, GAS1RR/RGMB-AS1-hsa-miR-3614-5p-AR/GXYLT2 could be involved in the occurrence and development of CAG in Tibetan plateau areas.

In addition, 204 circRNA-miRNA-mRNA (involving 14 mRNAs) relationship pairs were identified in circRNA-miRNA-mRNA network (Fig. 5). In the circRNA-miRNA-mRNA network, pink, blue, rectangles, triangles and rhombuses represent up-regulated, down-regulated, mRNAs, miRNAs and circRNAs, respectively. Among which, hsa_circ_0025836/hsa_circ_0082984/hsa_circ_0004657-hsa-miR-204-5p-CACNG8/JCAD/CCR5/MDFI, hsa_circ_0074486/hsa_circ_0008561-hsa-miR-34a-AR/GXYLT2, hsa_circ_0008561-hsa-miR-3614-5p-TMEM216/SUSD5, hsa_circ_0074486/hsa_circ_0008561-hsa-miR-129-RDX, hsa_circ_0082984/hsa_circ_0000676-hsa-miR-873-3p-TMC5 may be involved in the pathogenesis of CAG.



Figure 2. Volcano plots and heatmaps of DEmRNAs, DEmiRNAs, DElncRNAs, and DEcircRNAs between CAG and CNAG groups. (**A**–**D**) The volcano plots of DEmRNAs/DEmiRNAs/DElncRNAs/DEcircRNAs. Red dots represents up-regulated in the CAG group. Blue dots represents down-regulated in the CAG group. (**E**–**H**) The heatmaps of DEmRNAs/DEmiRNAs/DElncRNAs/DEcircRNAs. Red represents up-regulated, blue represents down-regulated. *CAG* chronic atrophic gastritis; *CNAG* chronic non-atrophic gastritis.



Figure 3. Visualization of lncRNA target mRNAs prediction in CAG and CNAG groups. Pink represents up-regulated, green represents down-regulated. Circles represents mRNAs, rhombuses represents lncRNAs. *CAG* chronic atrophic gastritis; *CNAG* chronic non-atrophic gastritis.

Identification of the common genes of Tibetan plateau key and ferroptosis related DEmRNAs in CAG patients based on online dataset

In the GEO dataset (involving non-Tibetan plateau areas), a total of 1148 DEmRNAs and 56 DElncRNAs were identified between CAG and CNAG groups. A total of 112 common DEmRNAs, 2 common DElncRNAs, 638 Tibetan plateau key DEmRNAs, and 240 Tibetan plateau key DElncRNAs were obtained by intersection processing of DEmRNAs and DElncRNAs from Tibetan plateau and non-Tibetan plateau areas (Fig. 6A,B). It is noted that eight common DEmRNAs, were further identified after taking the intersection of 283 ferroptosis genes and 638 Tibetan plateau key mRNAs, including CBS, SLC2A4, STAT3, ALOX15B, ATF3, IDO1, NOX4, and SOCS1.

Functional analysis of DEmRNAs in CAG patients in Tibetan plateau areas

To understand the mechanisms of DEmRNAs involved in CAG in Tibetan plateau areas, GO enrichment and KEGG pathway analyses were performed. KEGG analysis of mRNAs in the lncRNA-miRNA-mRNA regulatory network showed that GXYLT2 was enriched in other types of O-glycan biosynthesis, and AR was enriched in prostate cancer and oocyte meiosis pathways (Fig. 7A). AR, TMEM216, GXYLT2, TMC5, and SUSD5 were



Figure 4. The ceRNA network of lncRNA-miRNA-mRNA in CAG and CNAG groups. Pink represents up-regulated, blue represents down-regulated. Rectangles represents mRNAs, triangles represents miRNAs, V-shaped represents lncRNAs. *CAG* chronic atrophic gastritis; *CNAG* chronic non-atrophic gastritis.

involved in some GO terms (Fig. 7B). GO analysis of mRNAs in the circRNA-miRNA-mRNA regulatory network showed that RDX and CACNG8 were enriched in the T-tubules in terms of cellular components (Fig. 7C).

Functional analysis of 638 Tibetan plateau key DEmRNAs was also performed. These mRNAs were mainly enriched in the NOD-like receptor signaling pathway, cytokine–cytokine receptor interaction KEGG pathways (Fig. 7D). These mRNAs also participated in some biological processes, such as regulation of response to biotic stimuli, regulation of blood circulation, and type I interferon signaling pathway (Fig. 7E). KEGG pathways of Tibetan plateau key and ferroptosis-related DEmRNAs are shown in Fig. 7F. STAT3/SOCS1 is involved in the JAK-STAT signaling pathway. SLC2A4/STAT3 is involved in the adipocytokine and FoxO signaling pathways. Some enriched biological processes were identified, such as alpha-amino acid metabolic processes and the regulation of peptidyl-tyrosine phosphorylation (Fig. 7G).

Discussion

CAG is a digestive system disease, which is a precancerous lesion state of GC^{21,22}. Zhang et al. showed that the incidence of CG in plateau residents was higher than that in plain residents, and CAG was more common, which increased with increasing altitude²³. However, there has been little exploration of patients in the Tibetan plateau areas in recent years. Therefore, exploring the molecular mechanism of CAG in Tibetan plateau areas can provide a theoretical basis for the diagnosis, treatment, and pathogenesis of the disease. In recent years, ceRNA regulatory networks have played an important role in disease development and have been used in disease diagnosis, treatment, and prognosis prediction. CircRNAs and lncRNAs can be associated with multiple mRNAs and miRNAs. Based on the differential expression of lncRNAs, circRNAs, miRNAs, and mRNAs in CAG patients in Tibetan plateau areas, ceRNA regulatory networks (lncRNA/circRNA-miRNA-mRNA network) in CAG were constructed in this study. Moreover, Tibetan plateau key DEmRNAs and lncRNAs were also identified. It is noted that eight common DEmRNAs were further identified after taking the intersection of 283 ferroptosis genes and 638 Tibetan plateau key mRNAs. In addition, biological pathways that may be involved in CAG in Tibetan plateau areas were identified through functional analysis.



Figure 5. The ceRNA network of circRNA-miRNA-mRNA in CAG and CNAG groups. Pink represents up-regulated, blue represents down-regulated. Rectangles represents mRNAs, triangles miRNAs, rhombuses represents circRNAs. *CAG* chronic atrophic gastritis; *CNAG* chronic non-atrophic gastritis.

The lncRNA DRAIC is significantly correlated with the clinicopathological features of immune cell infiltration, tumor stage, and lymph node metastasis²⁴, and its expression is down-regulated in GC tissues and cell lines, functioning as a tumor suppressor²⁵. LncRNA GAS1RR is down-regulated in prostate cancer (PCa) tissues²⁶. RGMB-AS1 is up-regulated in GC cells and promotes GC progression by regulating the miR-22-3p/ NFIB axis²⁷. LINC00941 is highly expressed in GC tissues²⁸ and plays an important oncogenic role in GC²⁹. HasmiR-204-5p has been shown to inhibit lipopolysaccharide (LPS)-induced inflammatory processes in microglia³⁰, А



Figure 6. Venn diagrams of DEmRNAs (**A**) and DElncRNAs (**B**) between Tibetan plateau areas and non-Tibetan plateau areas in CAG and CNAG groups. *CAG* chronic atrophic gastritis; *CNAG* chronic non-atrophic gastritis.

and miR-204-5p can suppress the IL-2-mediated inflammatory response in HK-6 renal tubular epithelial cells³¹. Hsa-miR-34a-5p is involved in the regulation of TLR signaling and NF- κ B-mediated inflammatory responses³² and plays a crucial role in the occurrence of inflammation and autoimmune diseases³³. Down-regulated of has-miR-34a-5p was found in inflammatory factor-stimulated bronchial epithelial cell-derived exosomes³⁴, which was consistent with the expression of has-miR-34a-5p in CAG in our study. In addition, hsa-miR-34a-5p is a p53-regulated tumor suppressor involved in the progression of various cancers³⁵. Fang et al.³⁶ confirmed that miR-873-3p is a target gene of LINC00941, which is down-regulated in pancreatic adenocarcinoma (PAAD) tissues. In summary, miRNAs mediate various inflammatory responses; most lncRNAs are reported to be related to cancer, and their expression in CAG is a novel finding of our study.

CACNG8 is preferentially expressed in the hippocampus, cortex, and subcortical regions, which is critical for mood production, suggesting a relationship with psychiatric disorders³⁷. However, high expression of CACNG8 in CAG tissues was found for the first time in our study. We speculate that mood plays an important role in CAG development. AR shares high homology with GR and is a steroid hormone receptor with potent anti-inflammatory properties³⁸. Disruption of GR signaling can induce spontaneous gastric inflammation and chemosis in female mice³⁹. GXYLT2 is considered an important gene that regulates canonical Notch signaling, participates in human tumor progression, and is closely related to tumor immune infiltrating cells and immune genes^{40,41}. Zhang et al.⁴² showed that high levels of TMC5 are activators of PI3K/AKT, RAS/MAPK, and TSC/ mTOR, and it has been reported that activation of these pathways may lead to dysregulation of cell survival and ultimately tumorigenesis⁴³ and various cancers⁴⁴. These genes are involved in the process of inflammation and immune regulation and play an important role in the progression of CAG. In this study, we identified regulatory relationship pairs of hsa_circ_0082984-hsa-miR-204-5p-CACNG8, lncRNA DRAIC/has_circ_0008561-hsa-miR-34a-5p-AR/GXYLT2, lncRNA GAS1RR/RGMB-AS1/hsa_circ_0008561-hsa-miR-3614-5p-TMEM216/SUSD5, and LINC00941/hsa_circ_0082984-hsa-miR-873-3p-TMC5 that may play an important role in CAG.

In addition, through the screening of differential genes between the Tibetan and non-Tibetan plateau areas, it was further proved that patients with CAG in Tibetan plateau areas had unique mRNA and lncRNA expression patterns. The KEGG pathway of common genes of Tibetan plateau key and ferroptosis-related DEmRNAs showed that STAT3/SOCS1 was involved in the JAK/STAT pathway, and SLC2A4/STAT3 was involved in the adipocytokine and FoxO signaling pathways. Helicobacter pylori infection induces many pro-inflammatory signaling pathways, leading to gastric inflammation and carcinogenesis, and is one of the early response pathways to Helicobacter pylori infection, which mediates immune regulatory processes and contributes to immune escape and the development of GC⁴⁵. The FOXO signaling pathway is involved in oxidative stress and inflammation in Parkinson's⁴⁶. Eating disorders and abnormal body weight may be associated with dysregulation of the adipocytokine signaling pathway⁴⁷, which may be related to the occurrence of gastric diseases. Enrichment analysis of the common genes of Tibetan plateau key and ferroptosis-related DEmRNAs further indicated that the exploration of markers in patients with CAG is a meaningful study.

However, the present study also has a certain degree of limitation. Firstly, the sample size of the sequencing data was small, and it is necessary to continue to expand the sample for further validation. Secondly, the specific molecular mechanisms of the identified lncRNA, circRNA, miRNA and mRNA were still unclear and need to be investigated by a large number of in vitro experiments in the future.

Conclusions

In summary, some pairs of lncRNA/circRNA-miRNA-mRNA regulatory networks may be involved in the occurrence and development of CAG. The JAK-STAT, adipocytokine, and FoxO signaling pathways are closely related to the occurrence of CAG. This study is helpful for exploring the mechanism of the occurrence and development of CAG in Tibetan plateau areas.



Figure 7. KEGG and GO enrichment analysis of DEmRNAs between CAG and CNAG groups in the Tibetan plateau areas. (**A**, **B**) KEGG and GO enrichment analysis of DEmRNAs in mRNA-miRNA-lncRNA network; (**C**) GO enrichment analysis of DEmRNAs in mRNA-miRNA-circRNA network; (**D**, **E**) KEGG and GO enrichment analysis of Tibetan plateau key DEmRNAs; (**F**, **G**) KEGG and GO enrichment analysis of common genes of Tibetan plateau key and ferroptosis related DEmRNAs. *CAG* chronic atrophic gastritis; *CNAG* chronic non-atrophic gastritis; *KEGG* Kyoto encyclopedia of genes and genomes; *GO* gene ontology.

Data availability

The datasets presented in this study can be found in online repositories. The name of the repository and accession number can be found below: Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE229902); GSE229902. GSE15322 dataset (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE153224) and GSE163416 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE163416) dataset were downloaded from the GEO database (https://www.ncbi.nlm.nih.gov/geo/).

Received: 27 October 2023; Accepted: 16 April 2024 Published online: 22 April 2024

References

- 1. Sipponen, P. & Maaroos, H. I. Chronic gastritis. Scand. J. Gastroenterol. 50, 657-667 (2015).
- Zhang, Y. et al. Validating traditional Chinese syndrome features in varied stages of chronic gastritis malignant transformation: Study protocol for a cross-sectional study. BMJ Open. 8, e020939 (2018).
- 3. Correa, P. Human gastric carcinogenesis: A multistep and multifactorial process–first American cancer society award lecture on cancer epidemiology and prevention. *Cancer Res.* **52**, 6735–6740 (1992).
- 4. Correa, P. A human model of gastric carcinogenesis. Cancer Res. 48, 3554-3560 (1988).
- 5. Shah, S. C., Piazuelo, M. B., Kuipers, E. J. & Li, D. AGA clinical practice update on the diagnosis and management of atrophic gastritis: Expert review. *Gastroenterology.* **161**, 1325-1332.e1327 (2021).
- 6. Du, Y. et al. Chronic gastritis in China: A national multi-center survey. BMC Gastroenterol. 14, 21 (2014).
- Dixon, M. F., Genta, R. M., Yardley, J. H. & Correa P. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am. J. Surg. Pathol. 20, 1161–1181 (1996).
- 8. Wu, X. *et al.* Genomic features and molecular function of a novel stress-tolerant *Bacillus halotolerans* strain isolated from an extreme environment. *Biology* **10**, 1030 (2021).
- 9. Guo, Y. *et al.* Genome of Helicobacter pylori strain XZ274, an isolate from a Tibetan patient with gastric cancer in China. *J Bacteriol.* **194**, 4146–4147 (2012).
- Dinger, M. E., Pang, K. C., Mercer, T. R. & Mattick, J. S. Differentiating protein-coding and noncoding RNA: Challenges and ambiguities. *PLoS Comput. Biol.* 4, e1000176 (2008).
- 11. Beermann, J., Piccoli, M. T., Viereck, J. & Thum, T. Non-coding RNAs in development and disease: Background, mechanisms, and therapeutic approaches. *Physiol. Rev.* 96, 1297–1325 (2016).
- 12. Liu, Y. et al. Noncoding RNAs regulate alternative splicing in Cancer. J. Exp. Clin. Cancer Res. 40, 11 (2021).
- Cui, W., Dang, Q., Chen, C., Yuan, W. & Sun, Z. Roles of circRNAs on tumor autophagy. Mol. Ther. Nucleic Acids. 23, 918–929 (2021).
- Yang, F. & Chen, Y. High-throughput sequencing and exploration of the lncRNA-circRNA-miRNA-mRNA network in type 2 diabetes mellitus. *BioMed. Res. Int.* 2020, 8162524 (2020).
- Zheng, Y. L. et al. Interactions among lncRNA/circRNA, miRNA, and mRNA in Musculoskeletal degenerative diseases. Front. Cell Dev. Biol. 9, 753931 (2021).
- Li, C. et al. Crosstalk of mRNA, miRNA, lncRNA, and circRNA and their regulatory pattern in pulmonary fibrosis. Mol. Ther. Nucleic Acids. 18, 204–218 (2019).
- 17. Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* 28, 27–30 (2000).
- 18. Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947-1951 (2019).
- Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587-d592 (2023).
- Liu, Y. et al. Development and validation of a combined ferroptosis and immune prognostic classifier for hepatocellular carcinoma. Front. Cell Dev. Biol. 8, 596679 (2020).
- de Vries, A. C. et al. Gastric cancer risk in patients with premalignant gastric lesions: A nationwide cohort study in the Netherlands. Gastroenterology. 134, 945–952 (2008).
- Fang, J. Y., Liu, W. Z., Shi, Y., Ge, Z. Z. & Xiao, S. D. Consensus on chronic gastritis in China-second national consensus meeting on chronic gastritis (14–16 September 2006 Shanghai, China). J. Dig. Dis. 8, 107–119 (2007).
- 23. Zhang, T. W. X., Hao, L., Wang, Z., Pang, Y., Chen, Wenhui. et al. Discussion on the pathogenesis of chronic gastritis in young people in plateau areas (with an analysis of 1 026 cases). *Chin. J. Dig. Endoscop.* 34–35 (2001).
- 24. Yao, Q., Zhang, X. & Chen, D. The emerging potentials of lncRNA DRAIC in human cancers. Front. Oncol. 12, 867670 (2022).
- 25. Zhang, Z., Hu, X., Kuang, J., Liao, J. & Yuan, Q. LncRNA DRAIC inhibits proliferation and metastasis of gastric cancer cells through
- interfering with NFRKB deubiquitination mediated by UCHL5. *Cell Mol. Biol. Lett.* 25, 29 (2020).
 26. Xiong Z. et al. GAS1RR, an immune-related enhancer RNA, is related to biochemical recurrence-free survival in prostate cancer. *Exp. Biol. Med. (Maywood).* 15353702221131888 (2022).
- Zhang, W., Zhan, F., Li, D., Wang, T. & Huang, H. RGMB-AS1/miR-22-3p/NFIB axis contributes to the progression of gastric cancer. *Neoplasma*. 67, 484–491 (2020).
- Liu, H. et al. Long non-coding RNA LINC00941 as a potential biomarker promotes the proliferation and metastasis of gastric cancer. Front. Genet. 10, 5 (2019).
- Luo, C. et al. Regulatory network analysis of high expressed long non-coding RNA LINC00941 in gastric cancer. Gene. 662, 103–109 (2018).
- Li, L. et al. Overexpression of SIRT1 induced by resveratrol and inhibitor of miR-204 suppresses activation and proliferation of microglia. J. Mol. Neurosci. 56, 858–867 (2015).
- Li, H., Wang, J., Liu, X. & Cheng, Q. MicroRNA-204-5p suppresses IL6-mediated inflammatory response and chemokine generation in HK-2 renal tubular epithelial cells by targeting IL6R. *Biochem. Cell Biol.* 97, 109–117 (2019).
- He, X., Jing, Z. & Cheng, G. MicroRNAs: New regulators of Toll-like receptor signalling pathways. *Biomed. Res. Int.* 2014, 945169 (2014).
- Song, A. F., Kang, L., Wang, Y. F. & Wang, M. MiR-34a-5p inhibits fibroblast-like synoviocytes proliferation via XBP1. Eur. Rev. Med. Pharmacol. Sci. 24, 11675–11682 (2020).
- Bartel, S. et al. Human airway epithelial extracellular vesicle miRNA signature is altered upon asthma development. Allergy. 75, 346–356 (2020).
- Wen, Y., Huang, H., Huang, B. & Liao, X. HSA-miR-34a-5p regulates the SIRT1/TP53 axis in prostate cancer. Am. J. Transl. Res. 14, 4493–4504 (2022).
- Fang, L., Wang, S. H., Cui, Y. G. & Huang, L. LINC00941 promotes proliferation and metastasis of pancreatic adenocarcinoma by competitively binding miR-873-3p and thus upregulates ATXN2. *Eur. Rev. Med. Pharmacol. Sci.* 25, 1861–1868 (2021).
- Peng, S. X. *et al.* SNP rs10420324 in the AMPA receptor auxiliary subunit TARP γ-8 regulates the susceptibility to antisocial personality disorder. *Sci. Rep.* 11, 11997 (2021).

- Claessens, F., Joniau, S. & Helsen, C. Comparing the rules of engagement of androgen and glucocorticoid receptors. Cell. Mol. Life Sci. 74, 2217–2228 (2017).
- Busada, J. T. et al. Endogenous glucocorticoids prevent gastric metaplasia by suppressing spontaneous inflammation. J. Clin. Invest. 129, 1345–1358 (2019).
- 40. Cui, Q. *et al.* GXYLT2 accelerates cell growth and migration by regulating the Notch pathway in human cancer cells. *Exp. Cell Res.* **376**, 1–10 (2019).
- 41. Wu, S., Qiu, S., Chen, W. & Ding, L. Prognostic signature GXYLT2 is correlated with immune infiltration in bladder cancer. *Disease Markers* 2022, 5081413 (2022).
- 42. Zhang, H., Zhang, X., Xu, W. & Wang, J. TMC5 is highly expressed in human cancers and corelates to prognosis and immune cell infiltration: A comprehensive bioinformatics analysis. *Front. Mol. Biosci.* **8**, 810864 (2021).
- 43. Porta, C., Paglino, C. & Mosca, A. Targeting PI3K/Akt/mTOR signaling in cancer. Front. Oncol. 4, 64 (2014).
- 44. Aoki, M. & Fujishita, T. Oncogenic roles of the PI3K/AKT/mTOR axis. Curr. Top. Microbiol. Immunol. 407, 153-189 (2017).
- 45. Li, X., Pan, K., Vieth, M. & Gerhard, M. JAK-STAT1 signaling pathway is an early response to helicobacter pylori infection and contributes to immune escape and gastric carcinogenesis. *Int. J. Mol. Sci.* 23, 4147 (2022).
- Singh, V. & Ubaid, S. Role of silent information regulator 1 (SIRT1) in regulating oxidative stress and inflammation. *Inflammation*. 43, 1589–1598 (2020).
- 47. Zhao, M., Li, X. & Qu, H. EDdb: A web resource for eating disorder and its application to identify an extended adipocytokine signaling pathway related to eating disorder. *Sci. China Life Sci.* 56, 1086–1096 (2013).

Author contributions

W.P., J.Y. and J.W. conceived and designed the study. L.C. and R.T. provided administrative support. X.C. and C. L. provided materials and samples. W.P. and T.R. conducted data collection and collation. W.P., J.Y. and J.W. conducted data analysis and interpretation. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

Funding

This study was funded by Sichuan Medical Association Digestive Endoscopy Special Committee (Jiexiang) Special Research Project (2021XHNJ35) and Local projects based on central guidance of China (XZ202301YD0031C).

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to J.Y.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2024